Company: TEM
Filing Date: 2025-02-25
Form Type: S-1
Source: 0001193125-25-034442
Chunk: 2

Company: Tempus AI, Inc.
Filing Date: 2025-02-25
Form: S-1
Chunk 2
---
 and among us, the
Seller and the Seller’s ultimate parent, Konica Minolta, Inc., a Japanese corporation, as guarantor, as stock consideration in connection with our acquisition of Ambry Genetics Corporation, a Delaware corporation, or Ambry, as more fully
described below in “Prospectus Summary—Acquisition of Ambry Genetics Corporation.” We are registering the offer and sale of the Shares from time to time by the selling stockholder to satisfy the registration rights granted to the
selling stockholder pursuant to the Purchase Agreement.

The selling stockholder may offer, sell or distribute all or a
portion of the Shares publicly or through private transactions at prevailing market prices or at negotiated prices after the expiration of any applicable lock-up period described in this prospectus. We will
not receive any of the proceeds from such sales of the Shares. We will bear all costs, expenses and fees in connection with the registration of these Shares. The selling stockholder will bear all commissions and discounts, if any, attributable to
their sale of the Shares. See the section entitled “Plan of Distribution.”

Our Class A common stock is
listed on the Nasdaq Global Select Market under the symbol “TEM.” On February 24, 2025, the last reported sales price of our Class A common stock was $69.57 per share.

We are an “emerging growth company” as defined under U.S. federal securities laws and, as such, have elected to
comply with reduced public company reporting requirements. This prospectus complies with the requirements that apply to an issuer that is an emerging growth company.

Investing in our securities involves a high degree of risks. You should review carefully the risks and uncertainties described in the section titled “ Risk Factors” beginning on page 5 of this prospectus, and under similar headings in any amendments or supplements to this prospectus.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities, or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.

The date of this prospectus is , 2025.

TABLE OF CONTENTS

| ABOUT THIS PROSPECTUS                                                      |     |  ii |
| CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS                       |     | iii |
| PROSPECTUS SUMMARY                                                         |     |   1 |
| RISK FACTORS                                                               |     |   5 |
| USE OF PROCEEDS                                                            |     |